Tango Therapeutics

Senior Director, Medical Affairs Strategy, Oncology

Tango Therapeutics  •  $296k - $444k/yr  •  Boston, MA (Onsite)  •  4 hours ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Company Overview

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.

Tango’s labs offices are located at 201 Brookline Avenue, in the vibrant Fenway area of Boston, Massachusetts.

Summary

Tango Therapeutics is seeking an experienced Senior Director, Medical Affairs Strategy, Oncology. Reporting to the Executive Director of Medical Affairs, this individual will shape and execute the medical strategy supporting product life-cycle management including registration and launch activities, evidence generation, external expert engagement planning, and patient advocacy partnerships.

The role will serve as a key strategic partner to Clinical Development, Clinical Operations, Medical Information, Scientific Communications, HEOR/RWE, Biomarkers/Diagnostics, Commercial, Market Access, Regulatory, Safety, Legal, Compliance, and Field Medical to ensure the evidence generated addresses the needs of healthcare professionals, patients, patient advocacy groups, and payers through late-stage development and launch.

Your Role:

Medical Affairs Strategy

  • Lead development and execution of integrated medical affairs plans across oncology programs
  • Lead medical launch-readiness planning, including pre-launch engagement objectives, resource planning, medical education planning, and integration with registrational and post-approval evidence plans
  • Translate clinical development objectives into evidence generation and stakeholder engagement strategies
  • Develop and maintain routine medical plans aligned with corporate objectives

Scientific Leadership

  • Provide scientific leadership, directing medical affairs team members supporting late-stage development, and partnering with Field Medical to translate medical strategy into engagement objectives, resource plans, tactics, and listening priorities that MSLs execute through scientific exchange
  • Ensure scientific consistency across programs and therapeutic areas
  • Define engagement planning objectives, resource plans, tactics, and insight-listening priorities for advisory boards, congress strategy, and external expert engagement, with scientific exchange executed by Field Medical MSLs

Evidence Generation

  • Lead the Medical Affairs evidence-generation strategy through late-stage development and launch
  • Prioritize evidence gaps and develop plans to address scientific and clinical questions arising from late-stage and registrational studies
  • Oversee real-world evidence, outcomes research, and post-approval evidence planning

HEOR and RWE

  • Provide medical input to HEOR and RWE strategies supporting value demonstration, in partnership with the HEOR partners
  • Collaborate with Market Access and Commercial teams to generate evidence relevant to payers and healthcare systems
  • Guide protocol development and data interpretation

IIS and Collaborative Research

  • Develop governance and strategy for investigator-sponsored studies
  • Evaluate research proposals and prioritize the IIS portfolio against late-stage evidence needs
  • Manage external scientific collaborations and academic partnerships
  • Ensure alignment between IIS investments and organizational objectives

Patient Advocacy

  • Build and maintain relationships with patient advocacy organizations, incorporate patient perspectives into medical strategy and evidence planning, and ensure all engagement complies with applicable legal and compliance requirements

Cross-Functional Partnership

  • Partner with Clinical Development to support lifecycle evidence planning
  • Collaborate with Biomarker and Diagnostic teams on precision medicine strategies
  • Work closely with Medical Information, Scientific Communications, and Field Medical teams to ensure coordinated execution, including feeding field insights back into engagement planning

Medical Governance

  • Support medical review and governance activities
  • Ensure compliance with all legal, regulatory, and ethical requirements
  • Contribute to SOP development and medical affairs operating procedures

What You Bring:

Required

  • MD, PharmD, or PhD in a life sciences discipline; MD preferred
  • 12+ years pharmaceutical/biotech experience
  • 7+ years within oncology Medical Affairs
  • 4+ years of experience in Medical Affairs strategic roles
  • Demonstrated success leading cross-functional initiatives

Preferred

  • Experience supporting registration-enabling or launch-stage oncology products
  • Strong background in HEOR, RWE, or post-marketing evidence generation
  • Experience partnering and leading in cross-matrix teams, and engaging patient advocacy organizations
  • Precision oncology and biomarker experience
  • Small biotechnology company experience

We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Salary range

$296,000—$444,000 USD

Tango Therapeutics

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.

What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.

Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
Boston, Massachusetts
Year Founded
2017
Social Media